As of Q4'25, CLS reported R&D Expenses of USD 30.7M and SG&A Expenses of USD 71.2M, marking a notable increase in both categories compared to the previous quarter. The latest data point highlights that SG&A remains the dominant component of operating expenses, accounting for more than double the R&D outlay. From Q1'23 to Q4'25, the chart reveals a generally upward trend in both R&D and SG&A expenses, with some volatility, particularly in SG&A. R&D Expenses saw steady growth, peaking at USD 36.4M in Q3'25 before a slight pullback. SG&A Expenses fluctuated more significantly, with a sharp spike to USD 112.5M in Q1'25 followed by a substantial drop in Q2'25, then recovering to USD 71.2M by Q4'25. Overall, the data suggests increasing investment in both research and operational activities over the observed period.